Near-term strategies for biotech drug developers facing shifting healthcare dynamics
A dynamic convergence of economic, legislative, scientific, and technological influences is molding the future of the healthcare industry – with implications for biotech companies. Healthcare environments are becoming increasingly complex as drug developers increasingly make the transition to next-generation therapeutics, driving demand for clinical innovation. Against this backdrop, the industry continues to pioneer new approaches to engaging with patients, clinical trial teams, and healthcare providers. During a recent panel discussion, Goldman Sachs and Parexel shared perspectives on emerging trends and high-level developments to help biotechs plan their short- and near-term strategies.
Get more insights from our recent panel discussion with Goldman Sachs, entitled “Decoding Healthcare’s Future: A comprehensive analysis of investment, clinical research and regulatory dynamics.”
The views and opinions expressed by the authors are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs, or Parexel, for you to take any action.
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Related Insights
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Playbook
Are you using real-world evidence?
Feb 1, 2023
Blog
Preparing for a new era in European Market Access
Jul 22, 2022
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Article
Three strategies for articulating a coherent product value story
Dec 18, 2021
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
Australia: The Regulatory and Reimbursement Environment
Aug 28, 2023
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023